IL132537A0 - Truncated vegf-related proteins - Google Patents
Truncated vegf-related proteinsInfo
- Publication number
- IL132537A0 IL132537A0 IL13253798A IL13253798A IL132537A0 IL 132537 A0 IL132537 A0 IL 132537A0 IL 13253798 A IL13253798 A IL 13253798A IL 13253798 A IL13253798 A IL 13253798A IL 132537 A0 IL132537 A0 IL 132537A0
- Authority
- IL
- Israel
- Prior art keywords
- related proteins
- truncated vegf
- vegf
- truncated
- proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84298497A | 1997-04-25 | 1997-04-25 | |
PCT/US1998/007801 WO1998049300A2 (en) | 1997-04-25 | 1998-04-20 | Truncated vegf-related proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
IL132537A0 true IL132537A0 (en) | 2001-03-19 |
Family
ID=25288752
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL13253798A IL132537A0 (en) | 1997-04-25 | 1998-04-20 | Truncated vegf-related proteins |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0977854A2 (en) |
JP (1) | JP2001524828A (en) |
KR (1) | KR20010020259A (en) |
CN (2) | CN1680442A (en) |
AU (1) | AU7250298A (en) |
CA (1) | CA2287538A1 (en) |
EA (1) | EA199900861A1 (en) |
IL (1) | IL132537A0 (en) |
NZ (2) | NZ514872A (en) |
WO (1) | WO1998049300A2 (en) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6734285B2 (en) | 1994-03-08 | 2004-05-11 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 proteins and compositions |
US6608182B1 (en) | 1994-03-08 | 2003-08-19 | Human Genome Sciences, Inc. | Human vascular endothelial growth factor 2 |
US7109308B1 (en) | 1994-03-08 | 2006-09-19 | Human Genome Sciences, Inc. | Antibodies to human vascular endothelial growth factor 2 |
US7153827B1 (en) | 1994-03-08 | 2006-12-26 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 and methods of use |
US7186688B1 (en) | 1994-03-08 | 2007-03-06 | Human Genome Sciences, Inc. | Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2 |
DK0751992T3 (en) | 1994-03-08 | 2006-03-06 | Human Genome Sciences Inc | Karendothelial growth factor 2 |
US6040157A (en) | 1994-03-08 | 2000-03-21 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
US5932540A (en) | 1994-03-08 | 1999-08-03 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
US6783980B2 (en) | 1995-06-15 | 2004-08-31 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US7423125B2 (en) | 1995-08-01 | 2008-09-09 | Vegenics Limited | Antibodies to VEGF-C |
JPH11514976A (en) | 1995-09-08 | 1999-12-21 | ジェネンテク・インコーポレイテッド | VEGF-related proteins |
US7125714B2 (en) | 1997-02-05 | 2006-10-24 | Licentia Ltd. | Progenitor cell materials and methods |
CN1299407A (en) * | 1998-03-13 | 2001-06-13 | 人体基因组科学有限公司 | Vascular endothelial growth factor 2 |
DE19813774A1 (en) * | 1998-03-27 | 1999-09-30 | Max Planck Gesellschaft | Parapox virus-encoded vascular endothelial cell growth factor (PPV-VEGF) |
EP1121143A2 (en) * | 1998-03-27 | 2001-08-08 | Dorothea J. Eicher | Vegf and vegf-c as infant formula supplements |
CA2340598A1 (en) | 1998-09-08 | 2000-03-16 | Agouron Pharmaceuticals, Inc. | Modifications of the vegf receptor-2 protein and methods of use |
US6958147B1 (en) | 1998-10-26 | 2005-10-25 | Licentia Ltd | Use of VEGF-C to prevent restenosis |
AU768330B2 (en) * | 1998-10-26 | 2003-12-11 | Vegenics Limited | Use of VEGF-C or VEGF-D gene or protein to prevent restenosis |
EP1568375A1 (en) * | 1998-10-26 | 2005-08-31 | Ludwig Institute For Cancer Research | Use of VEGF-C or VEGF-D gene or protein to prevent restenosis |
DE69939484D1 (en) | 1998-10-28 | 2008-10-16 | Cornell Res Foundation Inc | METHODS FOR REGULATING ANGIOGENESIS AND VASCULAR INTEGRITY BY TRK RECEPTOR LIGANDS BDNF, NT-3 AND NT-4 |
US6783953B1 (en) | 1998-12-22 | 2004-08-31 | Janssen Pharmaceutica N.V. | Vascular endothelial growth factor-X |
US7223724B1 (en) | 1999-02-08 | 2007-05-29 | Human Genome Sciences, Inc. | Use of vascular endothelial growth factor to treat photoreceptor cells |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
WO2003104467A1 (en) | 2002-04-25 | 2003-12-18 | Crucell Holland B.V. | Means and methods for the production of adenovirus vectors |
US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
AU4643501A (en) * | 2000-02-04 | 2001-08-14 | Flanders Interuniversity Institute For Biotechnology (Vib) | Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke |
US7727971B2 (en) | 2000-02-04 | 2010-06-01 | Life Sciences Research Partners Vzw | Use of placental growth factor for treating ischemic muscle disease |
EP1604024A4 (en) * | 2000-04-06 | 2008-04-23 | Wayne P Franco | Methods of using growth factors for treating heart disease |
EP1157999A1 (en) * | 2000-05-24 | 2001-11-28 | Introgene B.V. | Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof |
NZ518077A (en) | 2000-08-04 | 2003-11-28 | Human Genome Sciences Inc | Biologically active fragments, analogues and derivatives of VEGF-2 for the treatment of peripheral artery diseases such as critical limb ischemia and coronary disease |
US7405278B2 (en) | 2000-08-10 | 2008-07-29 | Masabumi Shibuya | Chimeric human-type vascular endothelial cell growth factor |
EP1191104A1 (en) * | 2000-09-26 | 2002-03-27 | Introgene B.V. | Gene delivery vehicles and use thereof in the preparation of a medicament and/or vaccine |
US7235233B2 (en) | 2000-09-26 | 2007-06-26 | Crucell Holland B.V. | Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts |
US7067317B2 (en) | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
EP1341914A2 (en) | 2000-12-07 | 2003-09-10 | Sangamo Biosciences Inc. | Regulation of angiogenesis with zinc finger proteins |
CA2444632A1 (en) | 2001-04-13 | 2002-10-24 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
US7402312B2 (en) | 2001-04-13 | 2008-07-22 | Human Genome Sciences, Inc. | Antibodies to vascular endothelial growth factor 2 (VEGF-2) |
JP2005505510A (en) | 2001-06-20 | 2005-02-24 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | Stimulation of angiogenesis by VEGF-B |
PT1438049E (en) | 2001-10-15 | 2007-02-28 | Janssen Pharmaceutica Nv | Substituted 4-phenyl-4-(1h-imidazol-2-yl)-piperidine derivatives for reducing ischaemic damage |
WO2006055743A2 (en) * | 2004-11-18 | 2006-05-26 | Franco, Wayne | Compbination growth therapy and cell therapy for treatment of acute and chronic diseases of the organs |
US20120141424A1 (en) * | 2009-01-07 | 2012-06-07 | Vegenics Pty Limited | Materials and Methods for the Treatment of Hypertension |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1242149B (en) * | 1990-09-27 | 1994-02-16 | Consiglio Nazionale Ricerche | CODING NUCLEOTID SEQUENCE FOR A HUMAN PROTEIN WITH REGULATORY PROPERTIES OF ANGIOGENESIS |
EP1321526A3 (en) * | 1992-11-18 | 2003-07-02 | Arch Development Corporation | Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle |
US6645933B1 (en) * | 1995-08-01 | 2003-11-11 | Helsinki University Licensing Ltd. Oy | Receptor ligand VEGF-C |
US6100242A (en) * | 1995-02-28 | 2000-08-08 | The Regents Of The University Of California | Gene therapies for enhancing cardiac function |
US5928939A (en) * | 1995-03-01 | 1999-07-27 | Ludwig Institute For Cancer Research | Vascular endothelial growth factor-b and dna coding therefor |
CA2214439C (en) * | 1995-03-02 | 2002-12-17 | Amrad Operations Pty. Ltd. | A novel growth factor and a genetic sequence encoding same |
CA2224002A1 (en) * | 1995-06-06 | 1996-12-12 | Human Genome Sciences, Inc. | Human vascular endothelial growth factor 3 |
-
1998
- 1998-04-20 EP EP98919794A patent/EP0977854A2/en not_active Withdrawn
- 1998-04-20 NZ NZ514872A patent/NZ514872A/en unknown
- 1998-04-20 WO PCT/US1998/007801 patent/WO1998049300A2/en not_active Application Discontinuation
- 1998-04-20 CN CNA200510009104XA patent/CN1680442A/en active Pending
- 1998-04-20 CA CA002287538A patent/CA2287538A1/en not_active Abandoned
- 1998-04-20 CN CN98806232A patent/CN1260835A/en active Pending
- 1998-04-20 NZ NZ500530A patent/NZ500530A/en unknown
- 1998-04-20 JP JP54706298A patent/JP2001524828A/en not_active Ceased
- 1998-04-20 EA EA199900861A patent/EA199900861A1/en unknown
- 1998-04-20 KR KR1019997009857A patent/KR20010020259A/en not_active Application Discontinuation
- 1998-04-20 AU AU72502/98A patent/AU7250298A/en not_active Abandoned
- 1998-04-20 IL IL13253798A patent/IL132537A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU7250298A (en) | 1998-11-24 |
EP0977854A2 (en) | 2000-02-09 |
JP2001524828A (en) | 2001-12-04 |
WO1998049300A2 (en) | 1998-11-05 |
NZ500530A (en) | 2001-12-21 |
NZ514872A (en) | 2005-01-28 |
EA199900861A1 (en) | 2000-06-26 |
KR20010020259A (en) | 2001-03-15 |
CN1260835A (en) | 2000-07-19 |
WO1998049300A3 (en) | 1999-03-11 |
CN1680442A (en) | 2005-10-12 |
CA2287538A1 (en) | 1998-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL132537A0 (en) | Truncated vegf-related proteins | |
GB9718609D0 (en) | Fusion protein | |
PT1090128E (en) | Modified vitamin-k-dependent polypeptides | |
GB9724783D0 (en) | Novel polypeptides | |
ZA9710338B (en) | Proteins | |
IL133582A0 (en) | Mammalian neuro-growth factor like protein | |
GB9719879D0 (en) | Protein | |
GB9703681D0 (en) | Protein complemention | |
GB9718110D0 (en) | Peptides | |
GB9701710D0 (en) | Mammalian protein | |
ZA984322B (en) | Sucrose-binding proteins | |
GB9700154D0 (en) | Peptides | |
GB9720784D0 (en) | Protein | |
EP1037898A4 (en) | Secreted proteins | |
AU2002300742A1 (en) | Truncated Vegf-related Proteins | |
GB9722727D0 (en) | Proteins | |
GB9722003D0 (en) | Proteins | |
GB9707822D0 (en) | Proteins | |
GB9707499D0 (en) | Proteins | |
GB9703104D0 (en) | Proteins | |
GB9700121D0 (en) | Proteins | |
ZA971900B (en) | Modified proteins | |
GB9706119D0 (en) | Novel protein | |
GB9703850D0 (en) | Novel protein | |
GB9704252D0 (en) | Novel protein |